

● PRINTER RUSH ● (PTO ASSISTANCE)

Application :	09/84663	प् Examiner :	Atremova	GAU:	1651
From:	PAP	Location:	(DC) FMF FDC	Date:	5/12/05
Tracking #: 059/2630 Week Date: 3/1/0ソ					
	DOC CODE 1449 1DS CLM IIFW SRFW OATH 312 SPEC	DOC DATE	MISCELL Continuing Foreign Price Document I Fees Other	Data ority	
[RUSH] MESSAGE: Attention Chief Draftsparson: Please provide a new set of drawing sheets. A dark line traverses through digures.					
[XRUSH] RESPONSE:					

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.


REV 10/04







- ●: GLUCOSE (g/l)
- ■: MYCELIA (g/l)
- **▲**: Ph___

FIG. 3









•: CARBOHYDRATE (490nm)

O: PROTEIN (595nm)



CHEMICAL SHIFT (ppm)




O: UNTREATED

•: PRETREATED

■: POSTTREATED

FIG. 8a




Day after tumor implantation

O: UNTREATED

•: POLYSACCHARIDE - TREATED

☐: 0.1mg/kg ADRIAMYCIN - TREATED

■: POLYSACCHARIDE/0.1mg/kg ADRIAMYCIN -TREATED




O: UNTREATED

•: POLYSACCHARIDE - TREATED

☐: 0.3mg/kg ADRIAMYCIN - TREATED

■: POLYSACCHARIDE/0.3mg/kg ADRIAMYCIN -TREATED



O: UNTREATED

•: POLYSACCHARIDE - TREATED

☐: ADRIAMYCIN - TREATED

FIG. 9b




FIG. 10a






FIG. 10b





O: POLYSACCHARIDE (B16)

☐: POLYSACCHARIDE (NC1-H23)

•: ADRIAMYCIN (B16)

■: ADRIAMYCIN (NC1-H23)